Biologic agents have become a core component of therapeutic strategies for many
inflammatory rheumatic diseases. However, perhaps reflecting the specificity and generally …

Dealing with immunogenicity of biologicals: assessment and c... : Current Opinion in
Rheumatology Dealing with immunogenicity of biologicals: assessment and clinical relevance …

Anti-drug antibodies (ADAbs) develop in up to a third of patients treated with biologic agents,
with such immunogenicity being one of the main reasons for the loss of efficacy observed in …

Biological medications are able to induce an antidrug immune response. Immunogenicity
impairs clinical response and is associated with adverse events. Several confounding …

Introduction: The use of biologic disease-modifying anti-rheumatic drugs (DMARDs),
including therapeutic antibodies, antibody fragments and protein constructs that target key …

The first biological therapeutics in rheumatology are approaching patent expiration,
encouraging development of'follow-on'versions, known as' biosimilars'. Biological agents …

The first biological therapeutics in rheumatology are approaching patent expiration,
encouraging development of 'follow-on'versions, known as 'biosimilars'. Biological agents …

Monoclonal antibodies have proved to be extremely valuable additions to conventional
treatment for rheumatic diseases. However, despite the general trend towards …

Tumor necrosis factor-α inhibitors (TNFis) have revolutionized the management of
rheumatoid arthritis (RA), however despite considerable progress, only a small proportion of …

The wind of change is blowing in rheumatology. Rheumatologists may soon be exposed to
'biosimilars' of the medicines they routinely use as the European Medicines Agency (EMA) …